Biomedicines (Feb 2022)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

  • Alejandro Olivares-Hernández,
  • Edel del Barco Morillo,
  • Carmen Parra Pérez,
  • José Pablo Miramontes-González,
  • Luis Figuero-Pérez,
  • Teresa Martín-Gómez,
  • Roberto Escala-Cornejo,
  • Lorena Bellido Hernández,
  • Rogelio González Sarmiento,
  • Juan Jesús Cruz-Hernández,
  • María Dolores Ludeña de la Cruz

DOI
https://doi.org/10.3390/biomedicines10020360
Journal volume & issue
Vol. 10, no. 2
p. 360

Abstract

Read online

Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.

Keywords